Feature | June 13, 2014

Molecular Imaging Finds Novel Way to Knock Down Breast Cancer

Antibody-based molecular imaging agent hones in on newly targeted cell receptor that hints at more aggressive breast cancers and potential therapy

June 13, 2014 – For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent innovation in breast cancer biomarkers seeks the HER3 receptor instead, which could mean more comprehensive breast cancer imaging and potential treatments, say experts presenting data during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Breast cancer is one of the most prevalent forms of cancer among women. Certain kinds of tumors have been found to be more aggressive and associated with less than favorable prognoses compared to others. HER2 positive tumors are a hallmark of high-risk breast cancer. Emerging molecular imaging agents join tumor-seeking antibodies and signaling radioisotopes in one radiopharmaceutical that is injected at the time of imaging in order to track and report active receptors.

One of these investigational agents, known in the lab as Cu-64 DOTA-HER3 F(ab')2, does just that by hunting down HER3, a messenger that has been shown to speak for HER2-positive cancers in multiple tissue models when used in conjunction with a scanner called a positron emission tomography (PET) imaging system. This could encourage better, more personalized care for breast cancer patients.

“HER3 is thought to be an important mediator of resistance to the HER2 inhibitors class of anti-cancer therapies, which are used to treat HER2-positive breast cancer representing approximately 20 percent of all breast cancers,” said principal author Eric P. Wehrenberg-Klee, M.D., from Massachusetts General Hospital in Boston, Mass. “Imaging of HER3 expression may allow for better understanding of how prevalent HER3 over-expression is among HER2 positive breast cancer patients, which in turn may allow for appropriate patient selection for the addition of HER3 inhibitors currently in clinical development.”

The researchers expect that it may be another year or two before the agent will reach regulatory approval and enter general clinical practice.

For more information: www.snmmi.org

Related Content

Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
Fujifilm to Host Pediatric Imaging Best Practices Symposium at AHRA 2018
News | Pediatric Imaging | July 18, 2018
Fujifilm Medical Systems U.S.A. Inc. announced that it will offer educational opportunities and exhibit its latest...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Invision Diagnostics Installs VolparaEnterprise Software to Enhance Mammography Image Quality
News | Mammography | July 11, 2018
Invision Diagnostics, a provider of mobile mammography services across North and South Carolina, announced that it is...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Jeffrey Hoffmeister, M.D.

Jeffrey Hoffmeister, M.D.

Feature | Breast Imaging | July 05, 2018 | By Jeffrey Hoffmeister, M.D.
When women reach age 40, an annual mammogram becomes a necessary part of their healthcare ritual — regardless if they...
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
Overlay Init